Who are JS004 in combination with toripalimab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imjudo, tremelimumab (treme), Nivolumab in combination with Ipilimumab, Fotemustine and Ipilimumab, RANCAD, IO102-IO103.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/js004-in-combination-with-toripalimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

JS004 in combination with toripalimab — Competitive Intelligence Brief

JS004 in combination with toripalimab (JS004 in combination with toripalimab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 inhibitor (in combination with PD-1 inhibitor). Area: Oncology.

phase 3 CTLA-4 inhibitor (in combination with PD-1 inhibitor) CTLA-4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

JS004 in combination with toripalimab (JS004 in combination with toripalimab) — Shanghai Junshi Bioscience Co., Ltd.. JS004 is a CTLA-4 inhibitor that blocks immune checkpoint signaling, and when combined with toripalimab (a PD-1 inhibitor), it provides dual checkpoint blockade to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
JS004 in combination with toripalimab TARGET	JS004 in combination with toripalimab	Shanghai Junshi Bioscience Co., Ltd.	phase 3	CTLA-4 inhibitor (in combination with PD-1 inhibitor)	CTLA-4
Imjudo	TREMELIMUMAB	AstraZeneca	marketed	CTLA-4-directed Blocking Antibody [EPC]	CTLA-4	2022-01-01
tremelimumab (treme)	tremelimumab (treme)	AstraZeneca	marketed	CTLA-4 inhibitor	CTLA-4
Nivolumab in combination with Ipilimumab	Nivolumab in combination with Ipilimumab	Bristol-Myers Squibb	marketed	Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor)	PD-1 and CTLA-4
Fotemustine and Ipilimumab	Fotemustine and Ipilimumab	Italian Network for Tumor Biotherapy Foundation	phase 3	Chemotherapy + immune checkpoint inhibitor combination	DNA alkylation (fotemustine); CTLA-4 (ipilimumab)
RANCAD	RANCAD	TSH Biopharm Corporation Limited	phase 3	CTLA-4 inhibitor	CTLA-4
IO102-IO103	IO102-IO103	IO Biotech	phase 3	Personalized neoantigen vaccine + checkpoint inhibitor combination	Patient-specific neoantigens; CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 inhibitor (in combination with PD-1 inhibitor) class)

Shanghai Junshi Bioscience Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JS004 in combination with toripalimab — Competitive Intelligence Brief. https://druglandscape.com/ci/js004-in-combination-with-toripalimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab